BioCryst Pharmaceuticals, Inc. (BCRX) Stock Score, Valuation & Financial Research
BioCryst Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 30/100.
Quick answer for BCRX
BioCryst Pharmaceuticals, Inc. currently has a Wall Street Score of 30/100. The stored market price is $8.12. Its financial score is 18/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What BioCryst Pharmaceuticals, Inc. does
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including
BCRX financial snapshot
- Wall Street Score:
- 30/100
- Current price:
- $8.12
- Market capitalization:
- $2.06B
- Revenue:
- $940.6M
- Net income:
- $-384.7M
- Free cash flow:
- $327.4M
- Cash:
- $155.0M
- Total debt:
- $409.9M
- EPS:
- -1.44
- Financial score:
- 18/100
- Valuation score:
- 0/100
- Revenue score:
- 32/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $327.4M, showing positive cash generation.
- The balance sheet shows $155.0M of cash versus $409.9M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: BCRX increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 18/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BCRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.